Cardiac patients
Current study results on Heart Disorders and Diseases - Heart Failure have revealed that GLP-1RA (glucagon-like peptide-1 receptor agonists) can play a significant role in reducing heart failure exacerbations, improving patient's functional status, and impacting the global healthcare burden of heart failure. The research, conducted by the University
Cardiac patients
Current study results on Heart Disorders and Diseases - Heart Failure have revealed that GLP-1RA (glucagon-like peptide-1 receptor agonists) can play a significant role in reducing heart failure exacerbations, improving patient's functional status, and impacting the global healthcare burden of heart failure. The research, conducted by the University
Heart failure
A new study has shed light on the potential benefits of wearable devices in managing chronic heart failure (CHF), a condition that affects over 64 million people globally and often reduces quality of life. Researchers at the Institute of Medical Informatics in Heidelberg, Germany, conducted a mixed-methods study that involved
Heart failure
A new study has shed light on the potential benefits of wearable devices in managing chronic heart failure (CHF), a condition that affects over 64 million people globally and often reduces quality of life. Researchers at the Institute of Medical Informatics in Heidelberg, Germany, conducted a mixed-methods study that involved
Heart failure
A new study has shed light on the potential benefits of wearable devices in managing chronic heart failure (CHF), a condition that affects over 64 million people globally and often reduces quality of life. Researchers at the Institute of Medical Informatics in Heidelberg, Germany, conducted a mixed-methods study that involved
Heart failure
Researchers at Mayo Clinic have detailed new data in Nutritional and Metabolic Diseases and Conditions - Obesity and Diabetes, highlighting the role of systemic inflammation in the pathophysiology of heart failure. The study aimed to characterize the prevalence and correlates of systemic inflammation across the spectrum of heart failure, including
Artificial intelligence
Research has shown that heart failure (HF) is a leading cause of hospitalization and mortality worldwide, with significant management challenges due to its heterogeneity and frequent comorbidities. Despite advancements in treatment, HF poses significant burdens on healthcare, increased by the aging of populations and rising prevalence. Recent developments in artificial
Heart failure
Researchers at Johns Hopkins University have identified a complex syndrome known as heart failure with preserved ejection fraction (HFpEF), characterized by left ventricular diastolic dysfunction, elevated filling pressures, and normal ejection fraction. The prevalence of HFpEF is increasing, driven by an aging population and rising comorbidities including obesity, diabetes, and
Heart failure
A recent study has shed light on the accuracy of wearable devices in monitoring heart rate during cardiopulmonary exercise testing in patients with cardiovascular disease, particularly those with heart failure. The research, conducted by Itami City Hospital in Japan, evaluated the performance of the Fitbit Inspire 3 device in patients
Heart failure
New research has found that malnutrition is prevalent among heart failure patients in China, and is associated with poor prognosis. The study, published in the journal Nutrition, Metabolism and Cardiovascular Diseases, assessed the prognostic value of the Geriatric Nutritional Risk Index (GNRI) in acute heart failure (AHF) patients. The research
Atrial fibrillation
Investigators at the First Affiliated Hospital of Chongqing Medical University in China conducted a study to investigate the association between malnutrition and cardiovascular death in patients with atrial fibrillation. The researchers collected data from 570 consecutive patients diagnosed with heart failure and atrial fibrillation between January 2018 and December 2018.
Type 2 diabetes
A new study published in the journal Cureus has found that the implementation of guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF) remains suboptimal, despite its proven mortality benefits. The research, conducted at East Tennessee State University, analyzed data from three outpatient clinics and found that
